NIAID / BARDA Awards Elusys a $12 Million Contract to Further Develop Anthim, the Company’s Anthrax Therapeutic

Elusys to present at Bio Investor Forum 2007

Elusys Therapeutics appoints Robert D. Love as Chief Financial Officer

July 30th, 2007

Elusys appoints new Chairman of the Board and a Vice President of Development

June 21st, 2007

Elusys names Jeremy D. Middleton Vice President of Corporate Development

May 22nd, 2007 

April 20th, 2007

Elusys’ Anthrax Therapeutic, Anthim™, selected to “100 Great Investigational Drugs” list by R&D Directions

February 5th, 2007

Elusys Therapeutics to present at the 9th Annual Bio CEO & Investor Conference

January 4th, 2007

Elusys announces collaborative research and license agreement with Pfizer